As this is not a controlled study it is not possible to prove that the number of hospital admissions from hypoglycaemia was reduced, but it is likely that some of 103 hypoglycaemic episodes in insulin dependent diabetic patients would have resulted in admission to hospital for treatment of hypoglycaemia if the patients had not received treatment by ambulance staff. Ten patients required intravenous glucose over nine months; this contrasts with 50 patients who required intravenous glucose in the same hospital over a seven month period in 1987 (A Collier, personal communication.)3
the need for treatment in malignant hypercalcaemia is difficult, we suspect that adequate treatment of this condition remains inconsistent. All the cases ofprimary hyperparathyroidism in our survey were routine admissions for surgery. In view of our previous experience it is likely that the unexplained hypercalcaemia was due to primary hyperparathyroidism.
Comment
The most surprising change over the past decade has been the enormous increase in hypercalcaemia associated with chronic renal failure, which occurred in 81 of the 162 patients in our survey. In 32 patients the calcium concentration was greater than 3 0 mmol/l. Fifty three of the 81 patients were receiving calcium or vitamin D supplementation, and in 44 cases the serum calcium concentration returned to normal after reducing or stopping vitamin D or calcium supplementation. Twenty patients had hypercalcaemia which settled without treatment. Only two of the 81 patients subsequently required parathyroidectomy. Twenty one patients in our study developed hypercalcaemia after receiving a renal transplant. Two of these patients became normocalcaemic after stopping calcium supplementation. The others did not require treatment.
In this study there were five cases of transient perioperative hypercalcaemia in liver transplant recipients, probably due to the large intraoperative infusion of calcium during the transplant operation.
The incidence of hypercalcaemia among renal patients seems, at least in part, to be due to calcium carbonate replacing aluminium hydroxide as a phosphate binder, with its concomitant advantages of the avoidance of aluminium toxicity and simultaneous calcium supplementation. The increased incidence of hypercalcaemia with calcium carbonate has been noted in previous studies.4 Although the incidence of symptomatic hypercalcaemia seemed low, we suggest that the treatment of the hypercalcaemia of chronic renal failure with calcium supplements should be monitored more carefully.
We were disappointed that the treatment of the hypercalcaemia of malignancy seemed not to have improved over 10 years despite marked improvement in the efficacy of therapeutic measures available.
